Navigation Links
Cylene to Present Advances with Industry's Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
Date:11/16/2010

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many different cancers. Three poster presentations will reveal results from the Phase I clinical trial and highlight the potential of this novel compound for combination anticancer therapies.

"We are delighted to be exhibiting so much fresh science around our flagship compound CX-4945. These scientific disclosures complement our manuscript describing the mechanism of action of CX-4945, recently accepted by the journal Cancer Research. Presentations by Cylene at premier conferences and the publication of our science by peer reviewed journals further validate CK2 as target for anticancer therapy," stated William Rice, PhD, President and CEO of Cylene Pharmaceuticals. "At the EORTC conference we will showcase the latest clinical data from patients treated with CX-4945 and also the discoveries concerning the critical roles that CK2 plays in the DNA Damage Response and EGF-Receptor pathways. These data provide a strong mechanistic rationale for the combination of CX-4945 with many agents that target these same pathways for the treatment of multiple cancers. As a company we aim to fully exploit the potential of CX-4945 in the clinic and ultimately see that it translates to real benefit for those patients and families struggling with cancer."

The presentation schedule is:

Wednesday, November 17, 2010: 12:00 PM Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft m
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Questcor to Present at the Maxim Group Growth Conference
4. Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
5. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. WebMD to Present at the Citi 7th Annual U.S. Small/Mid Cap Conference
8. ERT to Present at Lazard Capital Markets 7th Annual Healthcare Conference on November 16, 2010
9. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
10. Philips and American Heart Association Present Fourth Annual Resuscitation Fellowship Award
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, will ... dbAccess Health Care Conference in Boston.   The ... a.m. Eastern Time / 8:20 a.m. Pacific Time.  The presentation ... website at http://www.neurocrine.com . If you ...
(Date:5/23/2013)... 23, 2013  Haemonetics Corporation (NYSE: HAE ) ... & EVP-Business Development, will present at The Deutsche Bank 38 ... Boston, MA on May 29, 2013 at 1:30pm ... The public may access Mr. Lindop,s presentation live ... Haemonetics Haemonetics (NYSE: HAE ) is ...
(Date:5/23/2013)... WASHINGTON , May 23, 2013 Hearing health ... active, feel younger, and remain socially and professionally engaged, he ... is the overriding message that the Better Hearing Institute ... support of National Men,s Health Week , which leads ... Health Week runs from June 10 through June 16. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... Hospital (MGH) Cancer Center has purchased four radiation therapy treatment ... and one Elekta Synergy® S. The order, which includes ... facility to offer patients a complete cancer treatment solution from ... systems position MGH to take advantage of Volumetric ...
... 2 The Asthma and Allergy Foundation of America (AAFA) ... annual research project ranks the fall,s 100 most challenging cities ... this year are: McAllen, TX (1); Wichita, KS (2); Louisville, ... In addition, according to a recent AAFA survey, fall ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 3New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 4New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 5New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 6
(Date:5/25/2013)... On May 20, 2013 the Sydney Morning Herald ... or plan for their eventual demise, but it is an ... Must-Do List to help people properly arrange for their last ... fact sheet.” , While not a formal document, this document ... It may include a summary of assets, debts, obtained ...
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
(Date:5/25/2013)... On May 25, Voices Against Brain ... advocacy, comments on a new study by the Max ... atmospheric plasma into brain cancer treatment may help when ... Science Daily article, physicists from the Max ... demonstrated the “synergistic effect of cold atmospheric plasma -- ...
(Date:5/25/2013)... 25, 2013 Many orthodontists have thought ... where exactly that cloud is. Most people would ... with to provide their cloud service and support would ... the service they're selling, they'd be wrong. Cloud ... (a secure, redundant facility that houses servers and related ...
(Date:5/25/2013)... According to world-renowned scholars, Queen Cleopatra VII was ... ever lived. Cleopatra’s legendary beauty moved nations and her ... men in her time. Cleopatra was also a scientist ... glowing and fresh, from her legendary milk baths to ... cyprus grass. , Cleopatra was said to possess the ...
Breaking Medicine News(10 mins):Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3
... cancer treatments using their knowledge about an obesity drug, orlistat ... in the laboratory . ,The drug binds and ... the protein's function and causes cell death. ,The ... Kridel and W. Todd Lowther at Wake Forest University School ...
... serve to repress an alcoholic's desire for drink, according ... of California-San Francisco . ,Varenicline, manufactured by ... the United States and Europe in 2006, has been ... reward system for addictive substances. ,The research ...
... that a large number of Internet searches are health ... the healthcare sector . This, claims Cambridge UK based ... and medical device manufacturers. According to a series of ... having to come to terms with informed patients who ...
... into a skin-care product that would wipe away wrinkles and ... ,The government's team of camel researchers, which has already pioneered ... found cosmetic properties in the hardy mammal's milk. ... a hospital's skin department to study it on 20 people ...
... or kill tumors in the pancreas of mice, US researchers ... of the deadliest human cancers ,The mutant gene ... kill themselves, researchers from The University of Texas MD Anderson ... more lethal mutant, called BikDD, which spares healthy tissue. ...
...
Cached Medicine News:Health News:Battle Between Google and Microsoft Could Trigger Revolution in Healthcare 2Health News:Mutated Gene Zaps Pancreas Cancer in Mice 2
... the parafollicular C-cells of the thyroid gland ... major action of calcitonin is to lower ... resulting in decreased mobilization of calcium from ... in conditions associated with high levels of ...
Calcitonin RIA Kit...
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
... been a standard requirement for ... during laser procedures, however, many ... that smoke plume generated from ... as smoke plume generated from ...
Medicine Products: